Celldex Therapeutics Inc

CLDX has broken decisively below its key support around 38.8–39.4 in a Stage 3 distribution context, confirming supply dominance. Short-term price is extended below declining EMAs with no exhaustion visible, justifying Sell Now into the broken support–turned–resistance zone for continuation participation.

• ↑Phase 1 CDX-622 delivered dose-dependent, durable serum tryptase reductions.
• ↑Two Phase 3 barzolvolimab trial readouts in late 2026 could spark stock gains.
• ↓Profitability remains deeply negative, highlighting ongoing net losses.